Quidel to Present at UBS Global Healthcare Conference
May 15 2018 - 5:00PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, announced today that it will present
at the UBS Global Healthcare Conference at the Grand Hyatt New
York hotel in New York, New York on Wednesday, May 23,
2018.
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present on Wednesday, May
23, 2018 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) with a
question-and-answer session scheduled immediately following the
presentation. During the presentation, the company will discuss
business and financial developments and trends. The company's
statements may contain or constitute material information that has
not been previously disclosed.
A live webcast and audio archive of the presentation will be
available via the Investor Relations section of the company’s
website at http://ir.quidel.com or by clicking the link below:
https://cc.talkpoint.com/ubsx001/052118a_as/?entity=37_XCP8GVS
Participants should allow approximately five to ten minutes
prior to the presentation's start time to visit the site and
download any streaming media software needed to listen to the
Internet webcast. A replay of the webcast will also be available on
the company’s website for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and
well-being of people around the globe through the development of
diagnostic solutions that can lead to improved patient outcomes and
provide economic benefits to the healthcare system. Marketed under
the Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage®
and InflammaDry® leading brand names, as well as under the new
Solana®, AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s
products aid in the detection and diagnosis of many critical
diseases and conditions, including, among others, influenza,
respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid
disease and fecal occult blood. Quidel's recently
acquired Triage® system of tests comprises a comprehensive test
menu that provides rapid, cost-effective treatment decisions at the
point-of-care (POC), offering a diverse immunoassay menu in a
variety of tests to provide healthcare providers with diagnostic
answers for quantitative BNP, CK-MB, d-dimer, myoglobin, troponin I
and qualitative TOX Drug Screen. Quidel’s research and development
engine is also developing a continuum of diagnostic solutions from
advanced immunoassay to molecular diagnostic tests to further
improve the quality of healthcare in physicians’ offices, hospital
and reference laboratories, and other alternate sites, like urgent
care centers and retail clinics, where healthcare is provided. For
more information about Quidel’s comprehensive product portfolio,
visit quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180515006666/en/
Quidel Contact:Quidel CorporationRandy StewardChief Financial
Officer(858) 552-7931orMedia and Investors Contact:Quidel
CorporationRuben Argueta(858) 646-8023rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Sep 2023 to Sep 2024